JPS59199627A - Method for stabilizing tablet - Google Patents
Method for stabilizing tabletInfo
- Publication number
- JPS59199627A JPS59199627A JP7340183A JP7340183A JPS59199627A JP S59199627 A JPS59199627 A JP S59199627A JP 7340183 A JP7340183 A JP 7340183A JP 7340183 A JP7340183 A JP 7340183A JP S59199627 A JPS59199627 A JP S59199627A
- Authority
- JP
- Japan
- Prior art keywords
- tablets
- additives
- contact
- antacid
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は粉末状態で接触させると化学反応を起こす2種
以上の添加物または/および薬理活性を有する物質(薬
物)を含有する錠剤の安定化法に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for stabilizing tablets containing two or more additives and/or pharmacologically active substances (drugs) that cause a chemical reaction when brought into contact in powder form.
2種以上の薬物または/および添加物を含有する錠剤に
おいて保管中に相互の接触による化学反応により着色変
化、具象の発生をきたすことがある。When tablets containing two or more drugs and/or additives are stored, chemical reactions due to mutual contact may cause discoloration or embossment.
このような保管中の分解を防止するため、例えばアスピ
リンと制酸剤を含有する錠剤においては、アスピリン(
酸性物質)と制酸剤(塩基性物質)の化学反応を防止す
るため二層錠あるいは二重錠にして安定化を図っている
。To prevent such decomposition during storage, for example, in tablets containing aspirin and antacids, aspirin (
In order to prevent chemical reactions between antacids (acidic substances) and antacids (basic substances), double-layer tablets or double-layered tablets are used to stabilize the drug.
しかし、これらの方法においては特殊な加工技術および
設備を必要とし、かつ製造コストの面で問題があった。However, these methods require special processing techniques and equipment, and have problems in terms of manufacturing costs.
そこで、本発明者等は2皿以上の薬物または/および添
加物を配合すると化学反応を起こす錠剤の安定化を図る
方法について鋭意検討した結果、化学反応を起こす薬物
または/および添加物を別々に錠剤にしたのち、分包包
装の1服用単位中(1包中)に共存させることにより安
定化を図ることが可能になることを見いだし本発明を完
成するに至った。Therefore, the present inventors have conducted intensive studies on a method for stabilizing tablets that cause chemical reactions when two or more drugs and/or additives are mixed together. The present inventors have discovered that stabilization can be achieved by making tablets and coexisting them in one dosage unit (in one package) in divided packaging, and have completed the present invention.
本発明によれば錠剤の製造において、特殊な加工技術お
よび設備を必要とせず、相互の接触により化学反−を起
こす、すべての薬物、添加物の錠剤化に適用でき、従来
、この種の錠剤の安定化の常道手段であった三層錠、二
重錠等の錠剤化が困難なため錠剤化を断念していた薬物
、添加物にも適用できるようになった。According to the present invention, no special processing technology or equipment is required in the production of tablets, and the present invention can be applied to tabletting all drugs and additives that cause chemical reactions when they come into contact with each other. It can now be applied to drugs and additives that had previously been abandoned due to the difficulty of forming them into tablets such as triple-layer tablets and double-layered tablets, which were the standard means of stabilizing drugs.
すなわち、本発明はこの種の錠剤の安定化の常道手段で
あった三層錠、二重錠等の特殊加工を必要とせず、単に
包装形態と組み合せて、相互の接触により化学反応を起
こす物質を別々に錠剤とし、分包包装の1服用単位中(
1包中)に共存させるだけで簡単に安定な錠剤を製する
ことを可能にした。In other words, the present invention eliminates the need for special processing such as triple-layer tablets and double-layer tablets, which have been the standard means of stabilizing tablets of this type, and instead uses substances that cause chemical reactions upon mutual contact in combination with the packaging form. Separate tablets, each packaged in one dose unit (
It has become possible to easily produce stable tablets by simply coexisting in the same package (in one package).
末法の包装形態としては分包包装が用いられ1服用単位
中(1包中)に錠剤を共存させることができる包装形態
であればよい。また包材については特に限定されない、
使用する物質に応じて防湿性の包材、しゃ光性の包材を
用いることがある。As for the packaging form of the powder, any packaging form may be used as long as it is a separate package and allows tablets to coexist in one dosage unit (in one package). In addition, there are no particular limitations on the packaging material.
Depending on the substance used, moisture-proof packaging materials or light-shielding packaging materials may be used.
末法に用いる薬物、添加物は特に限定されず粉末状態の
接触で化学変化を起こす物質であれば末法を適用するこ
とができる。The drugs and additives used in the powder method are not particularly limited, and the powder method can be applied to any substance that causes a chemical change upon contact with the powder.
例えば、アスピリンと制酸剤の組み合せ、官制で不安定
な酵素成分と制酸剤の組み合せ、およびビタミンCと制
酸剤の組み合せ等を挙げることができる。Examples include a combination of aspirin and an antacid, a combination of an unstable enzyme component and an antacid, and a combination of vitamin C and an antacid.
末法の適用分野としては医薬品、食品、農薬、肥料等の
すべての産業分野のものが該当する。The applicable fields of the law include all industrial fields such as pharmaceuticals, foods, agricultural chemicals, and fertilizers.
末法の場合、相互の接触により化学反応を起こす添加物
、薬物を別々に錠剤にしても1服用単位中(1包中)に
共存させるため、使用時には同時に取りだされ使用され
る。従って三層錠、二重錠等と同等の使用効果が期待さ
れる。In the case of powdered tablets, additives and drugs that cause chemical reactions when they come into contact with each other are made into tablets separately, but they coexist in one dosage unit (one package), so they are taken out and used at the same time. Therefore, it is expected to have the same effect of use as triple-layer tablets, double-layer tablets, etc.
このように本発明によれば粉末状態で接触させると化学
反応を起こす2種以上の薬物または/および添加物を含
有する錠剤の安定化を可能にすることができる。As described above, according to the present invention, it is possible to stabilize a tablet containing two or more drugs and/or additives that cause a chemical reaction when brought into contact in a powdered state.
次に実施例を記載するが、本発明はこれにより限定され
ない。Examples will be described next, but the present invention is not limited thereto.
実施例1
(1)アスピリンを含有した錠剤
アスピリン 200Wv
トウモロコシデンプン 36■タ ル
り 4 ツ
上記の分量になるようにアスピリンとトウモロコシデン
プンを混合したのち、乾式造粒法で顆粒を製する。Example 1 (1) Tablet containing aspirin Aspirin 200Wv Corn starch 36■ Tal
After mixing aspirin and corn starch in the above amounts, granules are produced by dry granulation.
顆粒にタルクを上記の分量になるように混合したのち錠
剤機により1錠重量240〜の直径9咽の錠剤を製した
。After mixing talc with the granules in the above amount, tablets each having a weight of 240 mm and a diameter of 9 mm were made using a tablet machine.
(2)制酸剤を含有した錠剤
炭酸マグネシウム 200■
トウモロコシデンプン 889ステアリン酸
マグネシウム 2■上記の分量になるように炭
酸マグネシウムとトウモロコシデンプンを混合したのち
、乾式造粒法で顆粒を製した。顆粒にステアリン酸マグ
ネシウムを混合したのち錠剤機により/錠重量240I
Ivの直径9瓢の錠剤を製した。(2) Tablet containing antacid Magnesium carbonate 200 ■ Corn starch 889 Magnesium stearate 2 ■ Magnesium carbonate and corn starch were mixed in the above amounts, and then granules were produced by dry granulation. After mixing magnesium stearate with granules, by tablet machine/tablet weight 240I
Tablets with a diameter of 9 gourds were prepared.
(3)分 包
アスピリンを含有した錠剤および制酸剤を含有した錠剤
を1個ずつグラシンとポリエチレンよりなる分包親装置
包中に充填して分包剤を製した。(3) Discounted tablets One tablet containing aspirin and one tablet containing an antacid were filled into a parent packaging device package made of glassine and polyethylene to prepare a packaged preparation.
比較例1
アスピリン 200q
炭酸マグネシウム 2(10■トウモロコシデ
ンプン 74qタ ル り
4 ηステアリン酸
マグネシウム 2■上記分量になるようにア
スピリン、JjJ?マグネシウムおよびトウモロコシデ
ンプンを混合して1錠重量480〜の直径12咽の錠剤
を製した。Comparative example 1 Aspirin 200q Magnesium carbonate 2 (10■ Corn starch 74q Tarri)
4 η Magnesium stearate 2 ■ Add aspirin and JjJ to the above amount. Magnesium and corn starch were mixed to form tablets with a diameter of 12 mm and each tablet weighing 480 ~.
錠剤を実施例1の包材を用いて錠剤1錠を含有した分包
剤を製した。A sachet containing one tablet was prepared using the packaging material of Example 1.
実施例1および比較例1の分包剤を40°C1相対湿度
75%の条件下で1力月間保存した結果、実施例1につ
いては全く変化を認めなかったが、比較例1については
着色変化と酢酸臭の発生を認めた。As a result of storing the sachets of Example 1 and Comparative Example 1 under the conditions of 40°C and 75% relative humidity for one month, no change was observed in Example 1, but no color change was observed in Comparative Example 1. and an acetic acid odor was observed.
Claims (1)
/および薬理活性を有する物質を含を別々に錠剤にした
のち、分包包装の1服用単位中(1包中)に共存させる
ことを特徴とする錠剤の安定化法。It is characterized in that the additives and/or pharmacologically active substances that cause a chemical reaction when they come into contact with each other in powder form are made into tablets separately and then coexisted in one dosage unit (in one package) in a separate package. Tablet stabilization method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7340183A JPS59199627A (en) | 1983-04-25 | 1983-04-25 | Method for stabilizing tablet |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7340183A JPS59199627A (en) | 1983-04-25 | 1983-04-25 | Method for stabilizing tablet |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS59199627A true JPS59199627A (en) | 1984-11-12 |
Family
ID=13517133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7340183A Pending JPS59199627A (en) | 1983-04-25 | 1983-04-25 | Method for stabilizing tablet |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS59199627A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4650669A (en) * | 1985-07-30 | 1987-03-17 | Miles Laboratories, Inc. | Method to make effervescent calcium tablets and calcium tablets produced thereby |
-
1983
- 1983-04-25 JP JP7340183A patent/JPS59199627A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4650669A (en) * | 1985-07-30 | 1987-03-17 | Miles Laboratories, Inc. | Method to make effervescent calcium tablets and calcium tablets produced thereby |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1338889C (en) | Morphine containing composition | |
RU2460340C2 (en) | Vitamin and mineral additives stability enhancement | |
EP2117506A2 (en) | Methods of making pharmaceutical components for customized drug products | |
CA1321754B (en) | Delivery system | |
RU2000109583A (en) | A SOLID DOSED MEDICINAL FORM FOR ORAL USE CONTAINING A COMBINATION OF METFORMINE AND GLYBENCLAMIDE | |
IE55140B1 (en) | Stable pharmaceutical tablet | |
US20210015776A1 (en) | Methods of stabilization of levothyroxine sodium tablets | |
KR101461841B1 (en) | Pharmaceuticals | |
JP2018076372A (en) | Anagliptin-containing solid formulation | |
CN103463120B (en) | A kind of stable type compound vitamin B tablet and preparation method thereof | |
US4292298A (en) | Pharmaceutical compositions containing paracetamol | |
CN102137664B (en) | Pharmaceutical solid preparation having active ingredients separated by boundary therein | |
CN1486611A (en) | Granulated CLO2 disinfectant and its production process | |
JPS59199627A (en) | Method for stabilizing tablet | |
JP6160263B2 (en) | Loxoprofen-containing pharmaceutical composition | |
JP2006511543A (en) | Stable topiramate formulation | |
JPH0196118A (en) | Gelatin composition | |
JPS59200650A (en) | Stabilization of solid product | |
JP6937195B2 (en) | Pharmaceutical composition | |
JPH037220A (en) | Stable tablet containing alkylcysteine or acid addition salt thereof | |
JPH08310953A (en) | Solid composition | |
JP4899304B2 (en) | Solid preparation for internal use containing ambroxol hydrochloride | |
RU2106141C1 (en) | Method for producing medicamentous form of nonnarcotic analgesic | |
JPH05201858A (en) | Solid pharmaceutical preparation | |
RU11710U1 (en) | PREPARATION FORM OF MIXTURE |